Avalyn Pharma (AVLN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.98
- Estimate
- -$0.56
- Surprise
- -73.5%
- Score today
- 5.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Avalyn Pharma (AVLN) reported a wider loss than forecast — diluted EPS of -$0.98 against the -$0.56 estimate (a 73.5% shortfall).
Coverage in the report window
- Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57 — benzinga, 2026-08-13
- Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate — benzinga, 2026-08-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates AVLN Sell at 5.7/10; no pre/post engine snapshot brackets this report.
0 of the last 2 quarters beat the estimate; this quarter's -73.5% surprise compares with a -1326.0% four-quarter average. Next scheduled report: 2026-11-16.
What argues against it
- Quality below floor (2.5 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -3.1%), Material insider selling (3 sells, 0.17% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $38.37
- Price target
- $52.91
- Stop
- $35.68
- Upside to target
- +37.9%
- Reward-to-risk
- 2.5:1
Risk check: RSI 79 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
AVLN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.70B
- P/E (fwd)
- -20.2
- 52-week range
- $24.15–$40.17
- Off 52-week high
- 4.5%
- RSI (14)
- 79
- Volume vs avg
- 0.92×
- Score today
- 5.7/10